In a statement, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, questioned whether the FDA's resolution of the shortage had taken into account demand for the compounded drug and "the number of patients wholl need to be transitioned from a compounded version to a FDA-approved version. "Thats likely hundreds of thousands of patients," Brunner said
Riesgo de productos falsificados o mal almacenados, especialmente por canales no oficiales
What has the FDA said previously about compounded versions of GLP-1 drugs
Is exercise important while using semaglutide
The scale doesn't tell the whole story
Notably, we achieved a balance in comorbidity profiles post-matching, with comparable rates of endocrine (88.5% vs 89.3%, p=0.6552), musculoskeletal (69.4% vs 68.3%, p=0.6713), and eye disorders (69.3% vs 67.2%, p=0.4332)